Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
1. Novo Nordisk lowered growth expectations for obesity and diabetes treatments. 2. Net profit for the quarter met analyst expectations but sales were below forecasts. 3. Shares fell over 50% this year due to competition and pricing pressures. 4. Novo's bid for Metsera competes with Pfizer amid antitrust allegations. 5. Mixed analyst opinions affecting stock confidence, with some cutting ratings.